Pharmacists and pharmacy technicians administering the human papillomavirus vaccine can now verify client immunization records through New Brunswick’s Electronic Health Record.
A patient profile must be established for every client receiving the inoculation. This file requires the individual’s name, address, medicare number, date of birth, and sex. Pharmacists must also record the vaccination date along with the product’s name and lot number.
Under the Public Health Act, all administrators of government-funded vaccines must log the vaccination act within one week of administration. To meet this rule, pharmacists input the data into the Drug Information System during that same seven-day window. The system then transmits the immunization details directly to the Public Health Information Solution.
Pharmacy operators hiring secondary staff to administer the vaccine must maintain a precise internal register. This document tracks the administrator’s identity and license number for every single patient encounter. The record may be kept in either paper or electronic formats.
- Direct EHR Access: Immunization providers can view patient history instantly via the provincial electronic health network.
- Strict Documentation Windows: Vaccine delivery details must be entered into the provincial drug system within seven days.
- Mandatory Proof of Receipt: Anyone receiving the vaccine must be given a computer-generated prescription receipt as an official immunisation certificate.
Section 14 of Regulation 2009-136 under the Public Health Act mandates that vaccine administrators provide proof of immunization to the recipient. A computer-generated prescription receipt satisfies this legal requirement.
Maintaining data accuracy is essential because these entries build a client’s official immunization file within the provincial registry. Staff must ensure that all entered demographics match the patient’s valid health card details prior to system submission.
Patients with a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to any component of the human papillomavirus vaccine or its previous doses must avoid subsequent administrations. Individuals experiencing acute, moderate-to-severe febrile illnesses should postpone vaccination until symptoms resolve.
- New Brunswick Public Health Act, Regulation 2009-136.
